financetom
Business
financetom
/
Business
/
Otis Worldwide Greenhouse Gas Reduction Targets Gain Science Based Targets Initiative's Approval
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Otis Worldwide Greenhouse Gas Reduction Targets Gain Science Based Targets Initiative's Approval
Apr 22, 2024 5:19 AM

07:47 AM EDT, 04/22/2024 (MT Newswires) -- Otis Worldwide ( OTIS ) said Monday the Science Based Targets initiative has approved its near-term greenhouse gas reduction targets.

The approved targets include slashing scope 1 and 2 emissions by 55% by 2033 from a 2021 base and reducing scope 3 emissions by 33% over the same period.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Netskope Seeks to Raise Up to $812.6 million in IPO
Netskope Seeks to Raise Up to $812.6 million in IPO
Sep 8, 2025
08:26 AM EDT, 09/08/2025 (MT Newswires) -- Netskope expects to raise between $717 million and $812.6 million in its initial public offering, according to a Monday filing with the US Securities and Exchange Commission. The cloud-security provider said it will offer 47.8 million class A common shares, expected to be priced between $15 and $17 per share. Underwriters have been...
Oncolytics Says Pelareorep Drug Shows 'Strong Efficacy, Translational Data' in Metastatic Colorectal Cancer
Oncolytics Says Pelareorep Drug Shows 'Strong Efficacy, Translational Data' in Metastatic Colorectal Cancer
Sep 8, 2025
08:28 AM EDT, 09/08/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) said Monday that data from three metastatic colorectal cancer, or mCRC studies for its immunotherapy pelareorep showed consistent efficacy signals, immune activation, and survival outcomes that exceeded benchmarks in multiple treatment settings. The REO 022 trial, which evaluates pelareorep in combination with Folfiri and bevacizumab in platinum refractory...
Marqeta Announces Appointment of Mike Milotich as CEO
Marqeta Announces Appointment of Mike Milotich as CEO
Sep 8, 2025
08:28 AM EDT, 09/08/2025 (MT Newswires) -- Marqeta ( MQ ) said Monday it has appointed Mike Milotich as chief executive officer, effective today. The company said Milotich has served as interim CEO since February, in addition to his role of chief financial officer. He will continue to serve as CFO until a successor has been identified, the company said....
Dianthus Therapeutics Says Claseprubart Showed Meaningful Improvements in Myasthenia Gravis Patients
Dianthus Therapeutics Says Claseprubart Showed Meaningful Improvements in Myasthenia Gravis Patients
Sep 8, 2025
08:29 AM EDT, 09/08/2025 (MT Newswires) -- Dianthus Therapeutics ( DNTH ) said Monday claseprubart demonstrated statistically significant and clinically meaningful improvements in a phase 2 study of adults with acetylcholine receptor antibody positive generalized myasthenia gravis. The therapy improved daily living and muscle strength scores as early as the first week and maintained benefits through week 13, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved